O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma
Completed · Phase 2
Conditions studied: Melanoma (Skin)
In brief
Phase II trial to study the effectiveness of O6-benzylguanine and carmustine in treating patients who have unresectable locally recurrent or metastatic melanoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than once chemotherapy drug may kill more tumor cells.
Key facts
- Study ID
- NCT00005961
- Run by
- National Cancer Institute (NCI)
- People needed
- 40
- Starts
- 2000-06-01
- Last updated by the study team
- 2013-02-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Illinois at Chicago Health Sciences Center — Chicago, Illinois, United States
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
- Decatur Memorial Hospital Cancer Care Institute — Decatur, Illinois, United States
- Evanston Northwestern Health Care — Evanston, Illinois, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- Lutheran General Cancer Care Center — Park Ridge, Illinois, United States
- Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
- Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Incorporated — Fort Wayne, Indiana, United States
- Michiana Hematology/Oncology P.C. — South Bend, Indiana, United States
- Mercy Ireland Cancer Center — Canton, Ohio, United States
- Ireland Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.